# Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC

> **NCT07729670** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 42 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DEVICE:** Multimodal Ablation
- **DRUG:** Neoadjuvant therapy
- **PROCEDURE:** Surgery
- **DRUG:** Adjunctive therapy

## Key facts

- **NCT ID:** NCT07729670
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2029-06
- **Final completion:** 2031-06
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729670, "Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*